Skip to content

Intensive pharmacovigilance of high-risk patients on hospital surgical wards.

Intensive pharmacovigilance of high-risk patients on hospital surgical wards.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON24911
Enrollment
10600
Registered
2011-02-23
Start date
2011-02-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

High risk patients on (orthopaedic) surgical wards

Interventions

1. A team of hospital pharmacists-clinical pharmacologists and internists-clinical pharmacologist will train participating hospital pharmacists to perform intensive pharmacovigilance in high-risk pati
2. Selection of high risk patients by a screening method
3. Intensive pharmacovigilance in high risk patients: Structured medication review will be performed combining clinical data and the list of current medication of the patient
4. Less intensive pharmacovigilance of low risk patients: Automatically finishing of alerts, which are known to be without harm for low risk patients (90%), without intervention of the hospital pharma
5. Education program for physicians and physician assistants: The most important pharmacologic items will be discussed and national and hospital guidelines, related to these subjects will be explained

Sponsors

Canisius Wilhelmina Hospital/ Department Clinical Pharmacy Radboud University Nijmegen Medical Center Mevr. J.M. Bos, hospital pharmacist Dr. C. Kramers, internist-clinical pharmacologist
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients admitted to wards of surgery and orthopaedic surgery of two hospitals during the study period, consisting of 6 months usual care and 6 months intervention (sample size per group is 5300).

Exclusion criteria

Exclusion criteria: N/A

Design outcomes

Primary

MeasureTime frame
Unintended drug related problems due to prescription errors, that lead to death, disability, increased length of hospital stay and readmission. Outcomes are judged by opinions of a panel of experts.

Secondary

MeasureTime frame
1. Serious prescription errors; 2. Non-serious prescription errors; 3. Guideline adherence. Outcomes are judged by opionions of a panel of experts. A pharmaco-economic evaluation will be performed.

Contacts

Public ContactJ.M. Bos

Canisius Wilhelmina Hospital Department Clinical Pharmacy PO box 9015

jm.bos@cwz.nl+31 (0)24 3657600

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)